• FEBRUARY 2, 2001

SBCH: 22% topline growth in FY01

Malted beverages major, Smithkline Beecham Consumer Healthcare Limited (SBCH), has posted a net profit of Rs 317 m in its fourth quarter ended December 31, 2000. This is only 5% up as compared to a net profit of Rs 301 m in the quarter ended December 31, 1999.

(Rs m) FY00 FY01 Change
Sales Turnover 7,057 8,583 21.6%
Other Income 239 289 20.9%
Total Income 7,296 8,873 21.6%
Profit after Tax/(Loss) 976 1,120 14.8%
Net profit margin (%) 13.8% 13.1%  
No. of Shares (eoy) (m) 45.4 45.4  
Diluted Earnings per share* 21.5 24.7  
Current P/e ratio   15.8  

However, the company's total income was higher by 31% to Rs 2.5 bn in 4QFY01. The company's annual performance was however, much better. In FY01, SBCH showed a 15% growth in bottomline and a 22% growth in topline.

SBCH is one of the few FMCG companies to show double digit growth in turnover on an annualised basis. The company's performance would have been much better but for its relatively poor 4QFY01 performance.

The poor performance in 4QFY01 also signals that the slowdown in consumption has started nagging SBCH. At the current levels, the SBCH stock quotes at a P/e multiple of 15.8 times its FY01 earnings. However, the bourses will now keenly watch the performance of SBCH in the coming months, so as to determine whether the poor performance in 4QFY01 was a freak incident, or such performances are likely to recur.

Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

Equitymaster Agora Research Private Limited (Research Analyst)
103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407